<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; CELG</title>
	<atom:link href="http://www.stockbloghub.com/tag/celg/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ISRG) Now is the Time to Buy Healthcare Stocks</title>
		<link>http://www.stockbloghub.com/2012/02/02/isrg-now-is-the-time-to-buy-healthcare-stocks/91149</link>
		<comments>http://www.stockbloghub.com/2012/02/02/isrg-now-is-the-time-to-buy-healthcare-stocks/91149#comments</comments>
		<pubDate>Thu, 02 Feb 2012 19:38:38 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91149</guid>
		<description><![CDATA[I’ve been talking a lot lately about the $4 trillion that’s about to fall into the laps of businesses in the healthcare sector due to the number of Baby Boomers who are now turning 65. And we know that the older we get, the more we spend on healthcare. Consider: The average senior takes between two and seven prescription medications. Two out of three seniors will suffer a physical or mental impairment. One out of three seniors will spend time in a nursing home. All of those things cost money – not to mention, chemotherapy, insulin, rehab stays, regular doctor appointments, weight loss programs and nutritional supplements. That’s why it’s a great time to put money to work in the sector. Revenue and earnings are going to explode higher in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/02/isrg-now-is-the-time-to-buy-healthcare-stocks/91149/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/01/18/celg-celgene-corporation-bull-of-the-day-2/90404</link>
		<comments>http://www.stockbloghub.com/2012/01/18/celg-celgene-corporation-bull-of-the-day-2/90404#comments</comments>
		<pubDate>Wed, 18 Jan 2012 20:45:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90404</guid>
		<description><![CDATA[We are maintaining our Outperform recommendation on Celgene Corp. (CELG) following impressive preliminary results disclosed for the fourth quarter (adjusted EPS up 46%) and full year 2011 (adjusted EPS up 36%). Preliminary adjusted revenues in the final quarter of 2011 came in at $1.28 billion, 22% above the year-ago figure. For 2011, sales came in at $4.8 billion, up 34%. The company also gave a bright outlook for 2012 with adjusted earnings expected to improve by 25%. We believe that Celgene, driven by its oncology portfolio and robust pipeline, should easily achieve the 2012 guidance. We believe that the current price represents an attractive entry point for long-term investors. Based on 2012 P/E estimates, the stock is trading at 17.4x earnings, compared to the industry average of 28.1. Our target ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/18/celg-celgene-corporation-bull-of-the-day-2/90404/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/26/celg-celgene-corporation-bull-of-the-day/85898</link>
		<comments>http://www.stockbloghub.com/2011/10/26/celg-celgene-corporation-bull-of-the-day/85898#comments</comments>
		<pubDate>Wed, 26 Oct 2011 13:43:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85898</guid>
		<description><![CDATA[We are upgrading Celgene Corporation (CELG) to Outperform from Neutral following strong second quarter results delivered by the company and the decision of CHMP that the benefits associated with Revlimid outweigh the risks in multiple myeloma patients. Celgene performed impressively in the second quarter of 2011 and beat the Zacks Consensus Estimate both in terms of revenues and earnings. Following the strong showing, Celgene upped its guidance for 2011. The stock has reacted favorably to the recent positive developments. Celgene, driven by its oncology portfolio and robust pipeline, is expected to continue performing impressively. We believe that the current price represents an attractive entry point for long-term investors. Our target price is $80.00. CELGENE CORP (CELG): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/26/celg-celgene-corporation-bull-of-the-day/85898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Take Advantage of the Fire Sale in Healthcare</title>
		<link>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490</link>
		<comments>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490#comments</comments>
		<pubDate>Fri, 19 Aug 2011 00:47:13 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Kindred Healthcare Inc.]]></category>
		<category><![CDATA[KND]]></category>
		<category><![CDATA[Lexicon Pharmaceuticals Inc]]></category>
		<category><![CDATA[LXRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NUVA]]></category>
		<category><![CDATA[NuVasive Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81490</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts to where they were just two weeks ago and are now at very attractive valuations. This is especially true in the healthcare sector, where names like Gilead Sciences (Nasdaq: GILD), which is down 12 percent, are still below where they were trading prior to the debt crisis decline. Whether the United States’ debt is rated AAA or AA+ should have no bearing on sales of Gilead’s leading HIV drugs or whether its newest drug, Quad, will receive FDA approval. The stock trades at just 11.2 times ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation Wins Label Expansion for Istodax</title>
		<link>http://www.stockbloghub.com/2011/06/21/celg-celgene-corporation-wins-label-expansion-for-istodax/76845</link>
		<comments>http://www.stockbloghub.com/2011/06/21/celg-celgene-corporation-wins-label-expansion-for-istodax/76845#comments</comments>
		<pubDate>Tue, 21 Jun 2011 19:00:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics Inc.]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76845</guid>
		<description><![CDATA[Recently, the US Food and Drug Administration (FDA) delivered a boost to Celgene Corporation (CELG) by approving its cancer drug Istodax (romidepsin) for an additional indication. The US regulatory body granted accelerated approval to Istodax for treating patients suffering from peripheral t-cell lymphoma (PTCL). The patients were treated at least once for PTCL. Istodax is already approved for treating patients suffering from T-cell lymphoma who have received at least one systemic therapy. The successful label expansion would boost Celgene’s top line significantly. We remind investors that Celgene filed a supplemental new drug application (sNDA) with the FDA, seeking to expand the label of Istodax to include the PTCL indication, in December 2010. The sNDA was based on safety and efficacy data from two mid-stage studies of Istodax in PTCL patients. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/21/celg-celgene-corporation-wins-label-expansion-for-istodax/76845/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharmaceutical Industry Outlook &#8211; March 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917</link>
		<comments>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917#comments</comments>
		<pubDate>Thu, 03 Mar 2011 01:14:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67917</guid>
		<description><![CDATA[The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition, including Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. These products generated more than $15 billion in sales in 2010. The effect of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Buys Abraxis BioSciences for $2.9 Billion</title>
		<link>http://www.stockbloghub.com/2010/10/25/celg-celgene-buys-abraxis-biosciences-for-2-9-billion/56337</link>
		<comments>http://www.stockbloghub.com/2010/10/25/celg-celgene-buys-abraxis-biosciences-for-2-9-billion/56337#comments</comments>
		<pubDate>Mon, 25 Oct 2010 16:42:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56337</guid>
		<description><![CDATA[The spate of acquisitions in the pharmaceutical industry continued with Celgene Corporation (CELG) completing the purchase of Abraxis BioScience Inc. for $2.9 billion in cash and stock. Celgene aims to bolster its cancer portfolio through this acquisition. The deal, which is expected to modestly hurt Celgene’s adjusted earnings in 2011 and be accretive thereafter, entitles the stockholders of Abraxis to $58 in cash and 0.2617 of Celgene stock for each Abraxis stock owned by them apart from a tradeable Contingent Value Right (CVR). The CVR makes its holder eligible to receive a pro rata share of future milestone and royalty payments. At the time of announcing the deal in June this year, Celgene said that the merger is expected to augment its 2015 revenue by approximately $1 billion. The merger ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/25/celg-celgene-buys-abraxis-biosciences-for-2-9-billion/56337/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Analyst Maintains Neutral Rating With $58 Target Price</title>
		<link>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443</link>
		<comments>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:16:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48443</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development and commercialization of drugs in the areas of cancer and immune/inflammatory diseases. The company’s key growth engine is Revlimid, currently approved for myelodysplastic syndrome (MDS) and second-line multiple myeloma (MM). The company is expanding its label into other indications. The drug, which is approved in approximately 50 countries for treating patients suffering from MM who have received at least one prior therapy in combination with dexamethasone, recently received marketing approval in Japan for the same indication. Another important growth driver at Celgene is Vidaza, which is approved for the treatment of MDS. The third marketed product at Celgene is Thalomid, approved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Analyst Maintains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249</link>
		<comments>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249#comments</comments>
		<pubDate>Wed, 18 Aug 2010 14:01:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48249</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development and commercialization of drugs in the areas of cancer and immune/inflammatory diseases. The company’s key growth engine is Revlimid, currently approved for myelodysplastic syndrome (MDS) and second-line multiple myeloma (MM). The company is expanding its label into other indications. The drug, which is approved in approximately 50 countries for treating patients suffering from MM who have received at least one prior therapy in combination with dexamethasone, recently received marketing approval in Japan for the same indication. Another important growth driver at Celgene is Vidaza, which is approved for the treatment of MDS. The third marketed product at Celgene is Thalomid, approved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Pharma Merger Mania is Heating Up</title>
		<link>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477</link>
		<comments>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477#comments</comments>
		<pubDate>Sat, 31 Jul 2010 16:17:01 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45477</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the healthcare sector, it’s all about pills. Lots and lots of pills. Blue pills, purple pills, sleeping pills, anti-depressants. They’re everywhere. It’s big business for Big Pharma and the companies are very good at marketing their products. Comedian Chris Rock referred to this trend, noting that drug companies keep naming symptoms until they find one that you have: Are you sad, are you lonely, are you hot, are you cold? You gotta take this pill! And they don’t even tell you what the pill does… they just keep naming symptoms. I saw a commercial the other day that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Big Pharma Has a Big Problem and Merger Mania is Heating Up</title>
		<link>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107</link>
		<comments>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107#comments</comments>
		<pubDate>Wed, 28 Jul 2010 18:53:53 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45107</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the healthcare sector, it’s all about pills. Lots and lots of pills. Blue pills, purple pills, sleeping pills, anti-depressants. They’re everywhere. It’s big business for Big Pharma and the companies are very good at marketing their products. Comedian Chris Rock referred to this trend, noting that drug companies keep naming symptoms until they find one that you have: Are you sad, are you lonely, are you hot, are you cold? You gotta take this pill! And they don’t even tell you what the pill does… they just keep naming symptoms. I saw a commercial the other day that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GIS) Company News for June 30, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/06/30/gis-company-news-for-june-30-2010-corporate-summary/42001</link>
		<comments>http://www.stockbloghub.com/2010/06/30/gis-company-news-for-june-30-2010-corporate-summary/42001#comments</comments>
		<pubDate>Wed, 30 Jun 2010 17:02:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[Processed & Packaged Goods]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Argon ST Inc]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[General Mills Inc.]]></category>
		<category><![CDATA[GIS]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Las Vegas Sands Corporation]]></category>
		<category><![CDATA[LVS]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[MON]]></category>
		<category><![CDATA[Monsanto Company]]></category>
		<category><![CDATA[STST]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[WYNN]]></category>
		<category><![CDATA[Wynn Resorts Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=42001</guid>
		<description><![CDATA[• General Mills (NYSE:GIS) raised its dividend before reporting inline fiscal fourth-quarter earnings of 41 cents a share, but its guidance for fiscal 2011 came in below Street expectations.  Revenues of $3.57 billion were in-line with Zacks projections of $3.57 billion, but were off 2.1% from a year earlier. The company sees 2011 earnings growth of 7-8% to $2.46-$2.48 • A supposedly-erroneous trade triggered the new, single-stock circuit breaker yesterday, halting trading in Citigroup (NYSE:C) shares for five minutes • According to a Bloomberg report, Apple (NASDAQ:AAPL) plans to start selling iPhones to Verizon (NYSE:VZ) starting in January, terminating AT&#38;T&#8217;s (NYSE:T) prior exclusive rights to US sales • 3M (NYSE:MMM) anticipates fiscal second quarter sales of $6.6 billion to $6.75 billion and organic sales volume growth of 16-18% • Boeing (NYSE:BA) said it agreed to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/30/gis-company-news-for-june-30-2010-corporate-summary/42001/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARRY) Array BioPharma and Novartis AG Sign Deal for Treating Cancer</title>
		<link>http://www.stockbloghub.com/2010/04/22/arry-array-biopharma-and-novartis-ag-sign-deal-for-treating-cancer/34746</link>
		<comments>http://www.stockbloghub.com/2010/04/22/arry-array-biopharma-and-novartis-ag-sign-deal-for-treating-cancer/34746#comments</comments>
		<pubDate>Thu, 22 Apr 2010 21:27:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Array BioPharma]]></category>
		<category><![CDATA[ARRY]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34746</guid>
		<description><![CDATA[Recently, Array BioPharma Inc. (ARRY) struck a deal with Novartis AG (NVS) to develop its small-molecule methyl ethyl ketone (MEK) inhibitors for treating cancer. The transaction is worth up to $467 million. Array is entitled to receive $45 million in upfront and milestone payments and a further $422 million subject to the achievement of other milestones. The global agreement pertains to the development of ARRY-162, ARRY-300 and other MEK inhibitors. ARRY-162 is currently undergoing early-stage development. The open-label, multiple dose trial is designed to determine the maximum tolerated dose apart from evaluating the safety, pharmacokinetics and pharmacodynamics of the candidate after daily oral administration in advanced cancer patients with solid tumors. The study has established a maximum tolerated dose. Array has started an expansion phase of this trial initially in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/arry-array-biopharma-and-novartis-ag-sign-deal-for-treating-cancer/34746/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Reports Earnings Ahead of Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/30/celg-celgene-reports-earnings-ahead-of-estimates/26457</link>
		<comments>http://www.stockbloghub.com/2010/01/30/celg-celgene-reports-earnings-ahead-of-estimates/26457#comments</comments>
		<pubDate>Sat, 30 Jan 2010 21:17:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26457</guid>
		<description><![CDATA[This morning, Celgene Corp. (CELG) reported fourth quarter and full year results for fiscal 2009. Quarterly Results The company earned 62 cents per share in the fourth quarter as opposed to 43 cents in the year-ago quarter. The Zacks Consensus Estimate for the quarter was 57 cents. Total revenues for the reported quarter came in at $761 million, an increase of 21.2% over the same period in 2008. The rise in total revenues was driven by worldwide market share gains Incorporatedreased duration of therapy of the company’s lead drug Revlimid, currently approved for Myelodysplastic Syndromes (MDS) and second-line Multiple Myeloma (MM), and reimbursement approvals.  Revlimid net sales came in at $497.1 million, which reflected an increase of 35 % over the year-ago period. Net sales of Thalomid, also approved for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/30/celg-celgene-reports-earnings-ahead-of-estimates/26457/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation Expands into Cancer Drugs</title>
		<link>http://www.stockbloghub.com/2010/01/18/celg-celgene-corporation-expands-into-cancer-drugs/25207</link>
		<comments>http://www.stockbloghub.com/2010/01/18/celg-celgene-corporation-expands-into-cancer-drugs/25207#comments</comments>
		<pubDate>Tue, 19 Jan 2010 00:29:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25207</guid>
		<description><![CDATA[Recently, Celgene Corporation (CELG) completed the acquisition of the privately held Gloucester Pharmaceuticals for $340 million in cash coupled with $300 million in future milestone payments. The deal is aimed at bolstering Celgene’s portfolio of cancer drugs. The deal is expected to be neutral to Celgene’s earnings in 2010 and accretive in 2011. Gloucester, founded in 2003, focused on developing new therapies to fulfill unmet medical needs in cancer treatment. The acquisition adds Istodax (romidepsin) to Celgene’s already established cancer portfolio. Istodax received clearance from the U.S. Food and Drug Administration (FDA) in November 2009 for treating CTCL patients who have received at least one prior systemic therapy. Celgene is expected to launch the drug in the first half of this year. Furthermore, it will pursue the European approval for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/celg-celgene-corporation-expands-into-cancer-drugs/25207/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation Announces Good News for Cancer Drug Study</title>
		<link>http://www.stockbloghub.com/2010/01/13/celg-celgene-corporation-announces-good-news-for-cancer-drug-study/24937</link>
		<comments>http://www.stockbloghub.com/2010/01/13/celg-celgene-corporation-announces-good-news-for-cancer-drug-study/24937#comments</comments>
		<pubDate>Thu, 14 Jan 2010 05:32:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24937</guid>
		<description><![CDATA[Yesterday, Celgene Corporation (CELG) announced that its cancer drug Revlimid met the main goal in a randomized, double-blind, multi-center late-stage study (IFM 2005 02). The study, sponsored by the Intergroupe Francophone du Myelome and University Hospital of Toulouse, evaluated Revlimid compared to placebo in patients suffering from multiple myeloma (MM) who had undergone an autologous stem cell transplant. The data was evaluated by an independent data and safety monitoring committee. &#8220;Autologous stem cell transplant&#8221; refers to a process where stem cells are removed from a person&#8217;s bone marrow before chemotherapy and reintroduced once through with chemotherapy. The objective of the exercise is for the stem cells to produce healthy new blood cells. The participants in the study received two cycles of the Celgene drug after undergoing a stem cell transplant ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/13/celg-celgene-corporation-announces-good-news-for-cancer-drug-study/24937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($JPM) JP Morgan Healthcare Conference in San Francisco</title>
		<link>http://www.stockbloghub.com/2010/01/13/jpm-jp-morgan-healthcare-conference-in-san-francisco/24897</link>
		<comments>http://www.stockbloghub.com/2010/01/13/jpm-jp-morgan-healthcare-conference-in-san-francisco/24897#comments</comments>
		<pubDate>Wed, 13 Jan 2010 23:58:21 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[WBMD]]></category>
		<category><![CDATA[WebMD Health Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24897</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, January 13, 2010: Issue #1174 Cautiously optimistic. Very cautiously optimistic. That’s how I’d describe the overall mood at this year’s JP Morgan Healthcare Conference in San Francisco. While folks are certainly in a better frame of mind than this time last year (when it seemed like we were in the middle of financial Armageddon), they’re still a bit gun-shy. But with the huge stock market rally and partnership/financing deals available again, the tone is more upbeat. As one banker said, “money is flowing into the market again.” These days, the conference is a major event and has become increasingly difficult to get into. Luckily, I’ve got the right credentials to get inside (without having to resort to a White House-style gatecrash) and give you ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/13/jpm-jp-morgan-healthcare-conference-in-san-francisco/24897/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Preliminary Earnings Results from Celgene</title>
		<link>http://www.stockbloghub.com/2010/01/12/celg-preliminary-earnings-results-from-celgene/24736</link>
		<comments>http://www.stockbloghub.com/2010/01/12/celg-preliminary-earnings-results-from-celgene/24736#comments</comments>
		<pubDate>Tue, 12 Jan 2010 23:27:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24736</guid>
		<description><![CDATA[Yesterday, Celgene Corporation (CELG) announced preliminary (unaudited) results for the fourth quarter of fiscal 2009 (ended December 31). The company earned 62 cents per share, beating the Zacks Consensus Estimate by 5 cents. Celgene earned 43 cents in the year-ago quarter. The preliminary results indicate that the company earned $2.08 in fiscal 2009, up 33%. This is above the Zacks Consensus Estimate by 23 cents. The company will report full year results on January 28, 2010. The results revealed that revenues have jumped in excess of 20% to about $755 million. Sales of Revlimid, marketed as a treatment for multiple myeloma and myelodysplastic syndrome Incorporatedreased nearly 35% in the quarter to about $495 million. Celgene is seeking to expand the Revlimid label. Fourth-quarter sales of Celgene’s cancer drug, Vidaza, registered ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/12/celg-preliminary-earnings-results-from-celgene/24736/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation Scores with Revlimid</title>
		<link>http://www.stockbloghub.com/2009/12/22/celg-celgene-corporation-scores-with-revlimid/23319</link>
		<comments>http://www.stockbloghub.com/2009/12/22/celg-celgene-corporation-scores-with-revlimid/23319#comments</comments>
		<pubDate>Tue, 22 Dec 2009 19:54:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23319</guid>
		<description><![CDATA[Celgene Corporation (CELG) announced recently that initial results from a late-stage study in multiple myeloma (MM) patients revealed that those treated with Revlimid underwent a 58% reduction in disease progression compared to placebo. The positive results caused shares of Celgene to close Dec. 18, 2009 at $55.95, up 10.5% from the previous day’s closing. The randomized, double-blind, multi-center study evaluated Revlimid in multiple myeloma patients who had received a stem-cell transplant. The trial, sponsored by the National Institutes of Health under an agreement with Celgene, comprises patients who have received autologous stem-cell transplants. Autologous stem-cell transplants refer to a process where stem cells are removed from a person&#8217;s bone marrow before chemotherapy, then reintroduced after chemotherapy. The objective of the exercise is for the stem cells to produce healthy new ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/22/celg-celgene-corporation-scores-with-revlimid/23319/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Drug Meets Study Goal</title>
		<link>http://www.stockbloghub.com/2009/12/16/celg-celgene-drug-meets-study-goal/23009</link>
		<comments>http://www.stockbloghub.com/2009/12/16/celg-celgene-drug-meets-study-goal/23009#comments</comments>
		<pubDate>Wed, 16 Dec 2009 22:50:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23009</guid>
		<description><![CDATA[Celgene Corp. (CELG) recently disclosed that its drug candidate, apremilast, for treating patients with moderate-to-severe plaque-type psoriasis, met key goals in a mid-stage study (n=352). The multi-center study, in which apremilast reduced the severity of moderate-to-severe psoriasis, saw patients receiving 10 mg, 20mg or 30mg of apremilast twice daily, or placebo. The data revealed that 41 % patients treated with 30 milligrams of apremilast, twice daily, underwent a 75 % reduction in symptoms. The symptoms were measured by a score known as the Psoriasis Area and Severity Index (PASI-75) after 16 weeks. However, only 6 % of patients who received a placebo reached that score. Furthermore, 29% of patients in the 20mg arm of apremilast and 11% of patients in the 10mg arm achieved a PASI-75 respectively. Celgene intends to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/celg-celgene-drug-meets-study-goal/23009/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation Presents Revlimid Data</title>
		<link>http://www.stockbloghub.com/2009/12/09/celg-celgene-corporation-presents-revlimid-data/22362</link>
		<comments>http://www.stockbloghub.com/2009/12/09/celg-celgene-corporation-presents-revlimid-data/22362#comments</comments>
		<pubDate>Thu, 10 Dec 2009 00:03:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22362</guid>
		<description><![CDATA[Celgene Corporation (CELG) announced recently that its cancer drug Revlimid reduced the risk of progression of the disease in newly diagnosed patients with multiple myeloma (MM) by 50%.  The data was presented at the 51st American Society of Hematology’s annual meeting in New Orleans. The data from a randomized, double-blind, late-stage study revealed that after less than 10 months of follow-up, patients treated with Revlimid combined with melphalan and prednisone, followed by Revlimid alone (MPR-R), lived longer without their disease progressing compared to those who took melphalan and prednisone followed by a placebo (MP). Patients who took only melphalan and prednisone lived an average of 13 months before the commencement of their disease progression. The median point had not yet been reached in the MPR-R group thereby suggesting that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/09/celg-celgene-corporation-presents-revlimid-data/22362/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ONXX) Onyx Pharmaceuticals gets Positive Data</title>
		<link>http://www.stockbloghub.com/2009/12/09/onxx-onyx-pharmaceuticals-gets-positive-data/22375</link>
		<comments>http://www.stockbloghub.com/2009/12/09/onxx-onyx-pharmaceuticals-gets-positive-data/22375#comments</comments>
		<pubDate>Wed, 09 Dec 2009 23:29:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22375</guid>
		<description><![CDATA[Recently, Onyx Pharmaceuticals (ONXX) came out with positive data from a phase IIb study of carfilzomib at the 51st annual meeting of the American Society of Hematology (ASH) in New Orleans. We are pleased to see that carfilzomib was found to be well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients. The company also stated that enrollment of 269 patients in this trial has been completed and data should be available in the second half of 2010. We believe favorable data could support a potential new drug application (NDA) filing by year-end 2010. Additionally, Onyx reported safety data from another study that showed carfilzomib can be used in patients over a long period of time even for those who are suffering from other illnesses. Carfilzomib was added to Onyx’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/09/onxx-onyx-pharmaceuticals-gets-positive-data/22375/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation to Expand</title>
		<link>http://www.stockbloghub.com/2009/12/08/celg-celgene-corporation-to-expand/22235</link>
		<comments>http://www.stockbloghub.com/2009/12/08/celg-celgene-corporation-to-expand/22235#comments</comments>
		<pubDate>Tue, 08 Dec 2009 18:50:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22235</guid>
		<description><![CDATA[Celgene Corporation (CELG) recently announced that it will purchase the privately held Gloucester Pharmaceuticals for $340 million in cash coupled with $300 million in future milestone payments. The deal is aimed at bolstering Celgene’s portfolio of cancer drugs. The transaction, which has been approved by the Board of Directors of both companies, is expected to be completed in the first quarter of 2010. The deal is expected to be neutral to Celgene’s earnings in 2010 and accretive in 2011. Gloucester, founded in 2003, focuses on developing new therapies aimed at fulfilling unmet medical needs for cancer treatment. The private entity focuses on developing therapies for cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL) and other hematological malignancies. The company’s lead drug Istodax (romidepsin) got U.S. Food and Drug Administration (FDA) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/08/celg-celgene-corporation-to-expand/22235/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYTR) Good News for CytRx Corporation</title>
		<link>http://www.stockbloghub.com/2009/12/04/cytr-good-news-for-cytrx-corporation/22040</link>
		<comments>http://www.stockbloghub.com/2009/12/04/cytr-good-news-for-cytrx-corporation/22040#comments</comments>
		<pubDate>Sat, 05 Dec 2009 01:27:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CYTR]]></category>
		<category><![CDATA[CytRx Corporation]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22040</guid>
		<description><![CDATA[CytRx Corp. (CYTR) announced that the U.S. Food and Drug Administration (FDA) lifted a clinical hold on its molecular chaperone candidate arimoclomol for treating patients suffering from amyotrophic lateral sclerosis (ALS or Lou Gehrig&#8217;s disease). The agency accepted a revised trial protocol while removing the two-year suspension. The candidate, in mid-stage studies, was placed on clinical hold by the agency in Jan 2008. The FDA cited the need for additional analysis from previously-completed animal toxicology studies. CytRx expects data from the revised trial protocol to be available within 18 months of the commencement of the trial. The study will evaluate safety and efficacy in arimoclomol- treated patients, at levels up to four times the dose administered in previous studies. The maximum dose of the candidate permissible for testing under the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/04/cytr-good-news-for-cytrx-corporation/22040/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ASH) Investing in the Biotech Sector: Here’s An Easy Way to Profit from Biotech Stocks</title>
		<link>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305</link>
		<comments>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305#comments</comments>
		<pubDate>Wed, 11 Nov 2009 21:51:36 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Chemicals - Major Diversified]]></category>
		<category><![CDATA[ARIA]]></category>
		<category><![CDATA[Ariad Pharmaceuticals Inc]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[IMGN]]></category>
		<category><![CDATA[Immunogen Inc]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[PARD]]></category>
		<category><![CDATA[Poniard Pharmaceuticals Inc]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20305</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, November 11, 2009: Issue #1135 Investing in the biotech sector can be risky – no doubt about that. But you know what? There are a lot of ways to make money from biotech stocks, too. If you know what to look for, that is. Two obvious examples include: Picking the company behind the next breakthrough drug for cancer or Alzheimer’s. Digging out companies that are likely takeover targets (something my colleague Louis Basenese does expertly in his Takeover Trader service), or landing lucrative drug partnership deals, which send the stocks higher. But there’s another excellent way that shorter-term investors can grab gains and profit from biotech sector… Follow the Biotech Sector Conference Buzz Throughout the year, the biotech sector holds many key conferences where ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Top Franklin Templeton Funds &#8211; Mutual Fund Education</title>
		<link>http://www.stockbloghub.com/2009/11/11/gild-top-franklin-templeton-funds-mutual-fund-education-2/20266</link>
		<comments>http://www.stockbloghub.com/2009/11/11/gild-top-franklin-templeton-funds-mutual-fund-education-2/20266#comments</comments>
		<pubDate>Wed, 11 Nov 2009 20:39:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20266</guid>
		<description><![CDATA[Franklin Biotechnology Discovery A (MAPTX) seeks capital appreciation by primarily investing in securities of biotechnology companies and discovery research firms. This non-diversified fund may invest a substantial portion of assets in equity securities of smaller capitalization companies with a market capitalization of less than $1.5 billion. Gilead Sciences Inc. (GILD), Celgene Corp. (CELG) and Genzyme Corp. (GENZ) are among the fund’s key holdings. Templeton Developing Markets A (TEDMX) seeks long-term capital appreciation through investment in securities of emerging economies. The fund may invest up to 20% of net assets in the securities of issuers in developed market countries. It may also invest in exchange-traded funds to gain exposure to certain segments of the equity markets while maintaining liquidity. J. Mark Mobius has been lead manager at the fund since October ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/gild-top-franklin-templeton-funds-mutual-fund-education-2/20266/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ONXX) Onyx Pharmaceuticals to Acquire Cancer Drugmaker Proteolix</title>
		<link>http://www.stockbloghub.com/2009/10/12/onxx-onyx-pharmaceuticals-to-acquire-cancer-drugmaker-proteolix/17418</link>
		<comments>http://www.stockbloghub.com/2009/10/12/onxx-onyx-pharmaceuticals-to-acquire-cancer-drugmaker-proteolix/17418#comments</comments>
		<pubDate>Mon, 12 Oct 2009 17:21:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17418</guid>
		<description><![CDATA[Recently, Onyx Pharmaceuticals (ONXX) announced that it will purchase privately held cancer drugmaker Proteolix for an upfront cash payment of $276 million. This transaction gives Onyx access to Proteolix&#8217;s lead compound, carfilzomib, a mid-stage multiple myeloma drug. Apart from the upfront cash payment, Onyx, which currently sells the liver and kidney cancer drug Nexavar along with Bayer AG, is also liable to pay $40 million in 2010 if carfilzomib achieves a development milestone and up to $535 million depending on the achievement of certain regulatory approvals for carfilzomib in the U.S. and Europe.  That is inclusive of a payment of $170 million if the Food and Drug Administration (FDA) decides to conduct a fast review of the drug. The all-cash transaction is expected to close in the fourth quarter of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/12/onxx-onyx-pharmaceuticals-to-acquire-cancer-drugmaker-proteolix/17418/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Top Franklin Templeton Funds &#8211; Mutual Fund Education</title>
		<link>http://www.stockbloghub.com/2009/09/23/gild-top-franklin-templeton-funds-mutual-fund-education/15888</link>
		<comments>http://www.stockbloghub.com/2009/09/23/gild-top-franklin-templeton-funds-mutual-fund-education/15888#comments</comments>
		<pubDate>Wed, 23 Sep 2009 19:48:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15888</guid>
		<description><![CDATA[Franklin Biotechnology Discovery A (MAPTX) seeks capital appreciation by primarily investing in securities of biotechnology companies and discovery research firms. This non-diversified fund may invest a substantial portion of assets in equity securities of smaller capitalization companies with a market capitalization of less than $1.5 billion. Gilead Sciences Inc. (GILD), Celgene Corp. (CELG) and Genzyme Corp. (GENZ) are among the fund’s key holdings. Franklin Real Estate Securities A (FREEX) was incepted in January 1994. The investment seeks maximize total return. The fund normally invests most of its assets in equity securities of real estate firms. It may invest up to 20% of assets in equity or debt securities of issuers engaged in businesses whose products and services are closely related to the real estate industry. Shareholders have to make a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/23/gild-top-franklin-templeton-funds-mutual-fund-education/15888/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARRY) Setback for Array BioPharma&#8217;s Drug</title>
		<link>http://www.stockbloghub.com/2009/09/08/arry-setback-for-array-biopharmas-drug/14607</link>
		<comments>http://www.stockbloghub.com/2009/09/08/arry-setback-for-array-biopharmas-drug/14607#comments</comments>
		<pubDate>Tue, 08 Sep 2009 23:24:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Array BioPharma]]></category>
		<category><![CDATA[ARRY]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14607</guid>
		<description><![CDATA[Last week, Array BioPharma (ARRY) announced that its most advanced, wholly-owned MEK inhibitor, ARRY-162, which was being developed to treat rheumatoid arthritis patients, failed to achieve a better response than placebo in a mid-stage trial. The study was designed to assess ARRY-162 in 201 patients with active rheumatoid arthritis who were not completely responsive to the drug methotrexate, the standard treatment. The subjects were on a stable dose of methotrexate for at least 6 weeks prior to their entry in the study. The 12-week study comprised of a placebo group and three different dose groups of ARRY-162. However, none of the treatment groups demonstrated a statistically significant response compared with the placebo group at 12 weeks. The placebo recipients in Latin America displayed much higher placebo response rates than patients ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/08/arry-setback-for-array-biopharmas-drug/14607/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LGND) Ligand Pharmaceuticals to Buy Neurogen</title>
		<link>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310</link>
		<comments>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310#comments</comments>
		<pubDate>Tue, 25 Aug 2009 21:36:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LGND]]></category>
		<category><![CDATA[Ligand Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Neurogen Corporation]]></category>
		<category><![CDATA[NRGN]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13310</guid>
		<description><![CDATA[Yesterday, Ligand Pharmaceuticals Inc. (LGND) announced it has agreed to purchase Neurogen (NRGN) for $11 million in stock as well as certain future cash payments based on licensing deals, real estate sales and other milestones. The deal, which is expected to close by the fourth quarter of this year, has been approved by both company boards. Additionally, Neurogen shareholders, representing approximately 33% of outstanding shares, have already given their nod in favor of the deal. The terms of the deal require Ligand to issue about 4 million new shares to Neurogen shareholders, which is equivalent to a purchase price of 16 cents per common share of Neurogen. Neurogen stockholders would hold 3% of the combined company. The transaction will give Ligand shareholders access to Neurogen&#8217;s partnership with Merck &#38; Co., ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARRY) Array Meets Expectations</title>
		<link>http://www.stockbloghub.com/2009/08/20/arry-array-meets-expectations-analyst-blog/12921</link>
		<comments>http://www.stockbloghub.com/2009/08/20/arry-array-meets-expectations-analyst-blog/12921#comments</comments>
		<pubDate>Thu, 20 Aug 2009 18:33:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Array BioPharma Inc.]]></category>
		<category><![CDATA[ARRY]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12921</guid>
		<description><![CDATA[Last week, Array BioPharma Inc. (ARRY) reported a fourth-quarter net loss of 55 cents per share which was in line with the Zacks Consensus Estimate. The company had a loss of 68 cents in the year-ago quarter. Net loss for fiscal 2009 was $2.67 per share, compared with $2.04 last year. Quarterly revenue came in at $5.5 million, representing a 10% decline from the comparable quarter in 2008. Sales for the full year fell by 13% to $25 million. The narrower quarterly loss was primarily attributable to lower spending on research and development. The company spent $21.3 million towards research and development for the quarter for the clinical advancement of its wholly owned drugs versus $28.4 million in year-ago quarter. Last January, Array had announced a restructuring plan of scaling ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/arry-array-meets-expectations-analyst-blog/12921/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

